Vaccines

VBI Vaccines Reports New CPT Code Issued for a 3-Antigen Prophylactic Hepatitis B Vaccine

Retrieved on: 
Thursday, July 1, 2021
Research, Infectious diseases, FDA, Clinical trials, Other Health, Biotechnology, Pharmaceutical, Health, Science, Oncology, Medical specialties, Clinical medicine, Medicine, Vaccines, Infectious causes of cancer, Hepatitis B, Hepadnaviridae, Vaccine, Hepatitis, HBsAg, Hepatitis D, CPT® Codes, Hepatitis B, VBI’s 3-Antigen Hepatitis B Vaccine, VBI Vaccines Inc., CPT® CODES, HEPATITIS B, VBI’S 3-ANTIGEN HEPATITIS B VACCINE, VBI VACCINES INC.

If approved, VBIs 3-antigen HBV vaccine candidate will be reported using the new code, differentiating it from other single-antigen HBV vaccines.

Key Points: 
  • If approved, VBIs 3-antigen HBV vaccine candidate will be reported using the new code, differentiating it from other single-antigen HBV vaccines.
  • VBIs vaccine candidate is the only 3-antigen hepatitis B vaccine, comprised of the S, pre-S1, and pre-S2 surface antigens of the hepatitis B virus, and is approved for use and commercially-available in Israel.
  • To learn more about VBIs 3-Antigen Hepatitis B vaccine candidate visit: https://www.vbivaccines.com/sci-b-vac/
    VBI Vaccines Inc. (VBI) is a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease.
  • VBI is committed to targeting and overcoming significant infectious diseases, including hepatitis B, coronaviruses, and cytomegalovirus (CMV), as well as aggressive cancers including glioblastoma (GBM).

Update: PharmaJet Needle-free COVID-19 Vaccine Trial

Retrieved on: 
Wednesday, June 30, 2021
Infectious diseases, Biotechnology, Pharmaceutical, Health, Medical specialties, Medicine, Drugs, Vaccines, Whooping cough, Clinical trials, COVID-19 vaccines, Vaccination, Vaccine, Pertussis vaccine, DPT vaccine, PharmaJet, BioNet, Technovalia, PHARMAJET, BIONET, TECHNOVALIA

PharmaJet , the maker of innovative, needle-free injection technology, today announced that patient enrollment has started for the phase 1 trial in Australia using its Needle-free Injection Systems to deliver a vaccine against SARS-CoV-2.

Key Points: 
  • PharmaJet , the maker of innovative, needle-free injection technology, today announced that patient enrollment has started for the phase 1 trial in Australia using its Needle-free Injection Systems to deliver a vaccine against SARS-CoV-2.
  • COVIGEN, a DNA-based vaccine was developed by French-Thai pharmaceutical company BioNet-Asia in collaboration with and Melbourne-based biotech Technovalia .
  • BioNet is the worlds only manufacturer of recombinant pertussis-only vaccine (Pertagen, aP vaccine) and a TdaP recombinant vaccine (Boostagen), containing a genetically-inactivated pertussis toxin (PTgen).
  • Technovalia is working with The Telehon Kids Institute, WA, to test BioNets recombinant acellular pertussis-only vaccine Pertagen in PertaPrime, a phase II-III randomized controlled trial in Australia.

Meissa Vaccines Begins Study of RSV Vaccine Candidate in Seronegative Children

Retrieved on: 
Wednesday, June 30, 2021
FDA, Other Health, Women, Seniors, Infectious diseases, Hospitals, Parenting, MEN, Children, Baby, Maternity, Clinical trials, Biotechnology, Science, Other Science, Consumer, Health, Medical specialties, Vaccination, Virology, Medicine, Clinical medicine, Vaccines, Atypical pneumonias, Respiratory syncytial virus vaccine, Human metapneumovirus, Respiratory syncytial virus, Vaccine, Attenuated vaccine, MV-012-968, AttenuBlockTM Platform, Meissa Vaccines, MV-012-968, ATTENUBLOCKTM PLATFORM, MEISSA VACCINES

Meissa Vaccines (Meissa), a biotechnology company developing vaccines to prevent serious viral respiratory infections, announced today the first seronegative participants have received MV-012-968, Meissas intranasal live attenuated RSV vaccine candidate, in a Phase 1c study in infants and young children.

Key Points: 
  • Meissa Vaccines (Meissa), a biotechnology company developing vaccines to prevent serious viral respiratory infections, announced today the first seronegative participants have received MV-012-968, Meissas intranasal live attenuated RSV vaccine candidate, in a Phase 1c study in infants and young children.
  • Meissa is developing MV-012-968 as a needle-free, adjuvant-free vaccine to protect infants and at-risk, older adults from respiratory syncytial virus (RSV).
  • We believe that our intranasal live attenuated RSV vaccine candidate, developed on Meissas AttenuBlockTM vaccine platform, offers the potential to finally immunize against RSV, which has evaded other vaccine technologies for more than 60 years, said Martin Moore, Ph.D., CEO and cofounder of Meissa Vaccines.
  • Meissa is advancing live attenuated vaccine candidates against respiratory syncytial virus (RSV), SARS-CoV-2 (COVID-19), and human metapneumovirus (hMPV).

Clover and Dynavax Announce Commercial Supply Agreement of Dynavax's CpG 1018 Adjuvant for Clover's COVID-19 Vaccine Candidate

Retrieved on: 
Wednesday, June 30, 2021
Vaccines, Medical specialties, Medicine, Clinical trials, COVID-19 vaccines, Adjuvants, SCB-2019, Science and technology in China, Immunology, COVID-19 vaccine, Immunologic adjuvant, Hepatitis B vaccine

Ryan Spencer, Chief Executive Officer of Dynavax commented, "Dynavax is excited for the opportunity to expand our partnership with Clover into an important commercial supply agreement to provide significant amounts of CpG 1018 for combatting the ongoing pandemic.

Key Points: 
  • Ryan Spencer, Chief Executive Officer of Dynavax commented, "Dynavax is excited for the opportunity to expand our partnership with Clover into an important commercial supply agreement to provide significant amounts of CpG 1018 for combatting the ongoing pandemic.
  • Clover's COVID-19 vaccine candidate is the combination of SCB-2019 and two adjuvants, Dynavax's CpG 1018 advanced adjuvant and aluminum hydroxide (alum).
  • Dynavax developed CpG 1018 to provide an increased vaccine immune response, which has been demonstrated in HEPLISAV-B.
  • Dynavax is also advancing CpG 1018 as a premier vaccine adjuvant through research collaborations and partnerships.

The Lancet Infectious Diseases Published Data from Sinovac’s Phase I/II Study, World’s First Published Study on Clinical Trial Results of a COVID-19 Vaccine in Healthy Children and Adolescents Aged 3 to 17 Years Old

Retrieved on: 
Wednesday, June 30, 2021
Children, Biotechnology, Health, General Health, Pharmaceutical, Other Science, Research, Infectious diseases, Consumer, Science, Clinical trials, Clinical trials, COVID-19 vaccines, COVID-19, Vaccines, Medicine, Pfizer–BioNTech COVID-19 vaccine, COVID-19 vaccine, CoronaVac, Nanocovax

This is the world's first published study on the use of a COVID-19 vaccine for children as young as 3 years old.

Key Points: 
  • This is the world's first published study on the use of a COVID-19 vaccine for children as young as 3 years old.
  • The study enrolled 552 participants, comprised of healthy children and adolescents aged 3-17.
  • From October 31 to December 2, 2020, 72 were enrolled in the phase I clinical study.
  • Between December 12 and December 30, 2020, 480 were enrolled in the phase II clinical study.

Clover and Dynavax Announce Commercial Supply Agreement of Dynavax's CpG 1018 Adjuvant for Clover's COVID-19 Vaccine Candidate

Retrieved on: 
Wednesday, June 30, 2021
Vaccines, Medical specialties, Medicine, Clinical trials, COVID-19 vaccines, Adjuvants, SCB-2019, Science and technology in China, Immunology, COVID-19 vaccine, Immunologic adjuvant, Hepatitis B vaccine

Ryan Spencer, Chief Executive Officer of Dynavax commented, "Dynavax is excited for the opportunity to expand our partnership with Clover into an important commercial supply agreement to provide significant amounts of CpG 1018 for combatting the ongoing pandemic.

Key Points: 
  • Ryan Spencer, Chief Executive Officer of Dynavax commented, "Dynavax is excited for the opportunity to expand our partnership with Clover into an important commercial supply agreement to provide significant amounts of CpG 1018 for combatting the ongoing pandemic.
  • Clover's COVID-19 vaccine candidate is the combination of SCB-2019 and two adjuvants, Dynavax's CpG 1018 advanced adjuvant and aluminum hydroxide (alum).
  • Dynavax developed CpG 1018 to provide an increased vaccine immune response, which has been demonstrated in HEPLISAV-B.
  • Dynavax is also advancing CpG 1018 as a premier vaccine adjuvant through research collaborations and partnerships.

Altimmune Announces Update on AdCOVID™ Phase 1 Clinical Trial

Retrieved on: 
Tuesday, June 29, 2021
Vaccines, Clinical trials, COVID-19 vaccines, COVID-19, Medicine, COVID-19 vaccine, Vaccine trial, Vaccine, Influenza vaccine, Nanocovax, H5N1 clinical trials

The Company also provided an update on its T-COVID Phase 1/2 clinical trial to evaluate the potential of T-COVID to prevent clinical worsening in patients with early COVID-19.

Key Points: 
  • The Company also provided an update on its T-COVID Phase 1/2 clinical trial to evaluate the potential of T-COVID to prevent clinical worsening in patients with early COVID-19.
  • The Phase 1 AdCOVID clinical trial is evaluating the safety and immunogenicity of the intranasally administered vaccine candidate in approximately 80 healthy adult volunteers between the ages of 18 and 55.
  • Based on these data, and in view of the highly competitive COVID-19 vaccine landscape, Altimmune is discontinuing further development of AdCOVID beyond the completion of this Phase 1 trial.
  • The immune response to AdCOVID was inferior to that seen in our NasoVAX influenza vaccine trial, commented Scot Roberts, PhD, Chief Scientific Officer at Altimmune.

Moderna Announces Emergency Use Authorization for its COVID-19 Vaccine Granted by Government of India

Retrieved on: 
Tuesday, June 29, 2021
Biotechnology, Infectious diseases, Other Health, Health, Pharmaceutical, COVID-19, COVID-19 vaccines, Clinical trials, Medicine, Vaccines, RNA vaccines, Medical research, Moderna COVID-19 vaccine, COVID-19 vaccine, Moderna, Vaccine, Sputnik V COVID-19 vaccine

I want to thank the government of India for this authorization, which marks an important step forward in the global fight against the pandemic, said Stphane Bancel, Chief Executive Officer of Moderna.

Key Points: 
  • I want to thank the government of India for this authorization, which marks an important step forward in the global fight against the pandemic, said Stphane Bancel, Chief Executive Officer of Moderna.
  • We are committed to making our COVID-19 vaccine available around the world.
  • Moderna has also received emergency (or other conditional, interim or provisional) authorization for use of its COVID-19 vaccine from health agencies in more than 50 countries and an Emergency Use Listing (EUL) from the World Health Organization (WHO).
  • Modernas COVID-19 vaccine is authorized pursuant to a Registration Certificate and a Permission to Import the vaccine for restricted use in an emergency situation in India, in adults aged 18 years and older.

Global $7.61 Billion Cancer Vaccines (Preventive, Therapeutic) Markets, 2015-2019, 2023F, 2025F, 2030F - ResearchAndMarkets.com

Retrieved on: 
Tuesday, June 29, 2021
Pharmaceutical, Health, Oncology, Vaccination, Medical specialties, Clinical medicine, Medicine, Cancer vaccines, Vaccines, Virology, Vaccine, Cancer vaccine, Vaccine therapy, Tumor antigen vaccine

Cancer Vaccines Global Market Global Market Report 2020-30: COVID-19 Growth and Change provides the strategists, marketers and senior management with the critical information they need to assess the global cancer vaccines global market market.

Key Points: 
  • Cancer Vaccines Global Market Global Market Report 2020-30: COVID-19 Growth and Change provides the strategists, marketers and senior management with the critical information they need to assess the global cancer vaccines global market market.
  • The cancer vaccines market consists of sales of vaccines used for the treatment of cancers and related services by entities (organizations, sole traders and partnerships) that produce vaccines for cancer treatment.
  • The cancer vaccines market covered in this report is segmented by type into preventive cancer vaccines; therapeutic cancer vaccines.
  • It is also segmented by technology into dendritic cells (DC) cancer vaccines; recombinant cancer vaccines; antigen/adjuvant cancer vaccines; whole cell cancer vaccines; viral vector & DNA cancer vaccines, by cancer type into prostate; cervical; colorectal; throat; others and by end-user into cancer treatment centers; research institutes.

Looking at Tumors Through a New Lens: New Research May Improve Efficacy of Glioblastoma Immunotherapy

Retrieved on: 
Tuesday, June 29, 2021
Cancer, Health, Medicine, Oncology, Melanoma, Glioblastoma, Vaccines, Cancer stem cell, Brain tumor

To improve the treatment efficacy, researchers are looking for vulnerabilities in surgically removed glioblastoma tissues, but this has been difficult due to the vast differences within the tumor and between patients.

Key Points: 
  • To improve the treatment efficacy, researchers are looking for vulnerabilities in surgically removed glioblastoma tissues, but this has been difficult due to the vast differences within the tumor and between patients.
  • To address this challenge, researchers at Institute for Systems Biology (ISB) and their collaborators developed a new way to study tumors.
  • The method builds mathematical models using machine learning-based image analysis and multiplex spatial protein profiling of microscopic compartments in the tumor.
  • Using melanoma to guide the interpretation of glioblastoma analyses, they identified the proteins that correlate with tumor-killing T cells, tumor growth, and immune cell-cell interactions.